BIZARRE: 10 - You Need To See This

Bladder Medication Mirabegron Recalled Nationwide Over an Impurity Linked to Cancer Risk

A lot of mirabegron tablets for overactive bladder were recalled nationwide due to an impurity. Here is the lot code patients should check now.

Medical Daily · Aug 14

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this…

The Economic Times · Aug 14

The First Independent Ratings of GLP-1 Telehealth Companies Left Out Every Platform Selling Only Compounded Drugs

U.S. News rated 20 GLP-1 telehealth platforms and excluded companies selling only compounded drugs, a boundary that shapes what shoppers see.

Medical Daily · Aug 14

Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore

Marksans Pharma shares surged after Q1FY27 profit jumped 174% YoY to Rs 159 crore. Revenue rose 35.6% to Rs 841 crore, while EBITDA hit a record Rs 213 crore, driven by strong growth in its UK and Europe formulation businesses.

The Economic Times · Aug 12

Maharashtra FDA cracks down on Ayurvedic drug makers, cancels 10 licences

Maharashtra FDA has launched a statewide crackdown on Ayurvedic drug manufacturers. Inspections revealed serious violations of manufacturing and quality control standards at many establishments. Following these findings, 135 manufacturers received show-cause notices for non-compliance issues. Ten manufacturers had their licenses permanently cancelled due to major violations affecting public health. The…

The Economic Times · Aug 12

Bombay HC warns Maharashtra FDA for ‘sword to kill mosquito’ approach as Cadila challenges drug ban

The Bombay High Court criticized the Maharashtra FDA for its drastic actions against companies. The court directed the regulator to grant hearings before taking severe measures. This directive came after Cadila Pharmaceuticals challenged the FDA's drug seizure and sales ban. The FDA agreed to revoke orders and provide hearings to…

The Economic Times · Aug 11

North Dakota Pulls All Kratom from Shelves as States Split Over an Unregulated Product

North Dakota banned all kratom products by executive order, going beyond concentrated 7-OH extracts and diverging from states that chose regulation.

Medical Daily · Aug 11

Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore

Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust twenty-two percent increase in operational revenue, reaching eight thousand seventeen crore rupees. The company experienced profitability challenges with an EBITDA reduction of seven point six percent compared to the previous…

The Economic Times · Aug 11

Thomas H. Jensen's Leadership at Allarity Therapeutics: Strengthening the Path Toward Personalized Cancer Care

Thomas H. Jensen leads Allarity Therapeutics in advancing personalized cancer care through precision medicine, combining molecular biology, computational analysis, and targeted therapies.

Medical Daily · Aug 11

Jubilant Pharmova shares decline 6% after Q1 profits falls 45% YoY

Jubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decline was attributed to weaker operating profitability and higher depreciation, while strong growth across segments, led by CDMO Sterile Injectables, boosted revenue.

The Economic Times · Aug 11